It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Leishmania infantum is the causative agent of visceral leishmaniasis transmitted by the bite of female sand flies. According to the WHO, the estimated annual incidence of leishmaniasis is one million new cases, resulting in 30,000 deaths per year. The recommended drugs for treating leishmaniasis include Amphotericin B. But over the course of the years, several cases of relapses have been documented. These relapses cast doubt on the efficiency of actual treatments and raise the question of potential persistence sites. Indeed, Leishmania has the ability to persist in humans for long periods of time and even after successful treatment. Several potential persistence sites have already been identified and named as safe targets. As adipose tissue has been proposed as a sanctuary of persistence for several pathogens, we investigated whether Leishmania infantum could be found in this tissue. We demonstrated both in cell cultures and in vivo that Leishmania infantum was able to infect adipocytes. Altogether our results suggest adipocytes as a ‘safe target’ for Leishmania infantum parasites.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Université Côte d’Azur, CHU, Inserm, C3M, Nice, France (GRID:grid.462370.4) (ISNI:0000 0004 0620 5402); Université Côte d’Azur, Inserm, C3M, Nice, France (GRID:grid.462370.4) (ISNI:0000 0004 0620 5402); Université Aix-Marseille, Marseille, France (GRID:grid.5399.6) (ISNI:0000 0001 2176 4817)
2 Université Côte d’Azur, CNRS, LP2M, Nice, France (GRID:grid.463981.1)
3 Université Côte d’Azur, CHU, Inserm, C3M, Nice, France (GRID:grid.462370.4) (ISNI:0000 0004 0620 5402); Université Côte d’Azur, Inserm, C3M, Nice, France (GRID:grid.462370.4) (ISNI:0000 0004 0620 5402)
4 Université Côte d’Azur, Inserm, C3M, Nice, France (GRID:grid.462370.4) (ISNI:0000 0004 0620 5402)
5 Université Côte d’Azur, Centre Commun de Microscopie Appliquée, Nice, France (GRID:grid.460782.f) (ISNI:0000 0004 4910 6551)
6 Unité des Toxines Bactériennes, Institut Pasteur, CNRS UMR2001, Paris, France (GRID:grid.428999.7) (ISNI:0000 0001 2353 6535)